COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Common Stock Issued
Cash raised by issuing new shares.
COMPASS Pathways plcNASDAQ: CMPS
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued grows in line with its trailing trend
Q1 FY2026 common stock issued of $343.3M rose 144.6% year over year, behind the +145.2% change in trailing-twelve-month common stock issued. Sequentially, it rose 3567720.2% from the prior quarter. Over 3 fiscal years it compounded at +584.4% a year.
Context
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +144.6% toward the trailing-twelve-month pace of +145.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 141.04M USD
- Year-over-year change
- +437.9%
- 4-year CAGR
- -2.3%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 141.04M | +437.9% |
| FY2024 | 2024-12-31 | 26.22M | -81.9% |
| FY2023 | 2023-12-31 | 144.94M | +32839.8% |
| FY2022 | 2022-12-31 | 440K | -99.7% |
| FY2021 | 2021-12-31 | 154.79M | — |
Common Stock Issued vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 common stock issued of $344.14M is the 3rd largest of the 11 companies compared; the peer median is $159.85M.
- Its year-over-year change of +145.2% is the 7th highest of 9, against a peer median of +425.6%.
- Over three fiscal years its annual growth of +584.4% compares with a peer median of +93.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.24B | +509.2% | +319.2% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $1.07B | +1407957.4% | +83.2% | — |
| LTM Mar 2026 | $344.14M | +145.2% | +584.4% | — | |
| LTM Mar 2026 | $276.62M | +93668.5% | +142.8% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $271.53M | +72.2% | +104.2% | 1357.6% |
| LTM Jun 2026 | $226.8M | +1490.1% | -12.7% | 6293.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $92.91M | — | — | — |
| LTM Jun 2026 | $85.9M | — | — | — | |
| LTM Jun 2026 | $51.05M | +154.8% | +82.6% | 4.5% | |
| LTM Jun 2026 | $9.27M | +341.9% | — | 1.0% | |
| LTM Mar 2026 | $3.43M | -97.7% | — | — | |
| Peer median (excluding CMPS) | $159.85M | +425.6% | +93.7% | 681.1% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| Deferred Income Tax | 22K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.64M | 13.12M | 17.28M | 19.52M | 13.59M |
| Change in Working Capital | (6.64M) | (30.67M) | 3.48M | 11.72M | (14.28M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (163K) | 2.5M | 864K | 6.59M | 2.03M |
| Other Working Capital | (6.47M) | (33.16M) | 2.62M | 5.13M | (16.32M) |
| Other Non-Cash Items | 1.8M | 3.27M | 86K | 4.46M | 131.1M |
| Operating Cash Flow | (67.75M) | (105.45M) | (97.38M) | (119.19M) | (157.24M) |
| Capital Expenditures | (334K) | (596K) | (66K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 2K | 0 | 0 |
| Investing Cash Flow | (334K) | (596K) | (64K) | 0 | 0 |
| Debt Repayment | 0 | 0 | 29.59M | 0 | 0 |
| Common Stock Issued | 154.79M | 440K | 144.94M | 26.22M | 141.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 600K | (690K) | 37.61M | (328.83K) |
| Financing Cash Flow | 156.65M | 1.04M | 173.83M | 63.82M | 140.71M |
| Effect of Forex Changes | (5.58M) | (24.96M) | 867K | 194K | 1.05M |
| Net Change in Cash | 82.99M | (129.97M) | 77.26M | (55.17M) | (15.48M) |
| Free Cash Flow | (68.08M) | (106.05M) | (97.44M) | (119.19M) | (157.24M) |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.